Page 1

Injectable Generic and Biosimilar Drugs – Potential Opportunities for Developers 2013 Order report by calling ReportsnReports.com at +1 888 391 5441 OR send an email on sales@reportsandreports.com with Injectable Generic and Biosimilar Drugs Market in subject line and your contact details. The Injectable Generics Market has been through a period of consolidation over the last few years as the leading companies have increased their presence through acquisition. The major players include Hospira, Sandoz (Novartis), Hikma Pharmaceuticals, Fresenius Kabi and Teva Pharmaceutical Industries. But interest in generic injectables has not been limited to established generic companies, as pharmaceutical majors like Pfizer have also become attracted to the market. This is hardly surprising with a global injectables market in the region of US$144 billion. While the lion’s share remains with the innovative industry for the time being, the generic injectables market is worth around US$12.2 billion and numerous high value injectable products will face patent expiry in major markets over the next decade. But, many of the big sellers are biological products and biosimilar approvals will only be possible for a few companies. Gaining regulatory approval in developed markets will be far more complex for biosimilars than for chemical generics and will involve costly clinical trials. To date, only a handful of companies have gained regulatory approval for biosimilars in Europe, and the US is likely to remain elusive to all but a select few. Among these, as the only US-based company with approval for biosimilars in the EU, Hospira is well positioned to take advantage of the potential US market. Complete Report is Available @ http://www.reportsnreports.com/reports/271919-injectable-generic-andbiosimilar-drugs-potential-opportunities-for-developers-2013.html. This report features in-depth reviews of 35 major products within specific therapy areas. Each product review examines mode of action, market approvals, competition, patents and market outlook, with tables and charts analysing revenue and including five-year forecasts and more (where available). In addition, the report analyses the major competitors such as Actavis, Frensenius Kabi, Hospira, Sandoz and more... What this report covers: • Executive Summary

Injectable Generic and Biosimilar Drugs – Potential Opportunities for Developers 2013


• • • • • • •

Injectable Drugs Market – Market Size and Opportunities Cancer – Hormonal Therapies, Chemotherapy, Monoclonal Antibodies, Supportive Therapies Diabetes Haematology Immunology – Multiple Sclerosis, Rheumatoid Arthritis Infection Major Competitors

Inquiry Before Buying @ http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=271919 The Injectable Generic and Biosimilar Drugs Report is the foolproof business resource for any industry executive that needs to fully understand the current products and major competitors of the injectable drugs market. The need for hard facts and statistics to back up everyday business decisions is essential and it is this report that can provide you with the answers. List of Tables Global Sales of Injectable Pharmaceuticals, 2011 - 2012 (US$ Million) 4 US Patent Expiry for Leading Injectable Drugs 6 Paragraph IV Certifications, January 2009 June 2013 7 Faslodex US Patents 9 Faslodex Sales, 2008 - 2012 (US$ Million) 10 Zoladex US Patents 12 Zoladex Sales, 2008 - 2012 (US$ Million) 12 Eloxatin US Patents 16 Eloxatin Sales, 2008 - 2012 (EUR & US$ Million) 16 FDA Approvals for Generic Oxaliplatin 18 Taxotere Sales, 2008 - 2012 (EUR & US$ Million) 20 EU Marketing Authorisations for Generic Docetaxel 21 Abraxane US Patents 23 Abraxane Sales, 2008 - 2012 (US$ Million) 23 Alimta US Patents 26 Alimta Sales 2008- 2012 (US$ Million) 26 Velcade US Patents 29 Velcade Sales by Company, 2008 - 2012 (US$ Million) 29 Rituxan/MabThera Sales, 2008 2012 (CHF & US$ Million) 33 Herceptin US Patents 36 Herceptin Sales, 2008 2012 (CHF & US$ Million) 36 Avastin Sales, 2008 2012 (CHF & US$ Million) 40

Injectable Generic and Biosimilar Drugs – Potential Opportunities for Developers 2013


Erbitux Sales by Company, 2008 2012 (EUR & US$ Million) 42 Five year Sales of Leading G CSF Brands (US$ Million)44 Filgrastim US Patents 45 Neupogen Sales, 2008 2012 (US$ Million) 46 EU Marketing Authorisations for Biosimilar Filgrastim 47 Neulasta Patents 50 Neulasta Sales, 2008 2012 (US$ Million) 50 Five Year Sales of Leading Insulin Brands (US$ Million) 52 Humulin Sales, 2008 2012 (US$ Million) 53 Humalog US Patents 55 Humalog Sales, 2008 2012 (US$ Million) 56 Lantus US Patents 57 Lantus Sales, 2008 2012 (EUR & US$ Million) 58 Apidra US Patents 59 Apidra Sales, 2008 2012 (EUR & US$ Million) 60 Levemir US Patents 61 Buy a copy of report @ http://www.reportsnreports.com/purchase.aspx? name=271919. Levemir Sales, 2008 2012 (DKK & US$ Million) 62 NovoRapid & NovoMix US Patents 64 NovoMix & NovoRapid Sales, 2008 2012 (DKK & US$ Million) 66 Epogen US Patents 68 Epogen/Eprex/Procrit Sales, 2008 2012 (US$ Million) 69 Biosimilar Eprex Approved in the EU 70 Aranesp US & EU Patents 73 Aranesp Sales, 2008 2012 (US$ Million) 73 Lovenox/Clexane Sales, 2008 2012 (EUR & US$ Million) 76 FDA ANDA Approvals for Mitoxantrone 79 Copaxone US Patents 81 Copaxone Sales by Company, 2008 2012 (US$ Million) 82 Avonex US Patents 85 Avonex Sales 2008 2012 (US$ Million) 85 Rebif Sales, 2008 2012 (EUR & US$ Million) 88 Betaferon/Betaseron & Extavia Sales, 2008 2012 (EUR & US$ Million) 90 Biosimilar Interferon Beta in Emerging Markets 91 Enbrel US Patents 94 Enbrel Sales by Company, 2008 2012 (US$ Million) 94 Humira US Patents 97 Humira Sales by Company, 2008 2012 (US$ Million) 98

Injectable Generic and Biosimilar Drugs – Potential Opportunities for Developers 2013


Remicade US Patents 100 Remicade Sales by Company, 2008 2012 (US$ Million) 101 Cubicin US Patents 105 Cubicin Sales, 2008 2012 (US$ Million) 106 Invanz US Patents 109 Invanz Sales, 2008 2012 (US$ Million) 109 Tygacil US Patents 112 Tygacil Sales, 2008 2012 (US$ Million) 112 Synagis US Patents 114 Synagis Sales, 2008 2012 (US$ Million) 115 PegIntron US Patents 116 PegIntron Sales, 2008 2012 (US$ Million) 117 Pegasys US Patent 119 Pegasys Sales, 2008 2012 (CHF & US$ Million) 119 Biosimilar Interferon Alfa in Emerging Markets 120 Actavis ANDA Approvals for Injectables, 2010 2013 127 Akorn ANDA Approvals for Injectables, 2010 2013 129 PharmaForce ANDA Approvals for Injectables, 2010 2013 130 Luitpold Pharmaceuticals ANDA Approvals for Injectables, 2010 2013 131 Amphastar ANDA Approval, 2011 132 Aurobindo ANDA Approvals for Injectables, 2010 2013 134 Claris Lifesciences FDA ANDA Approvals, 2010 2013 135 Dr Reddy’s ANDA Approvals, 2010 2013 137 APP ANDA Approvals, 2010 2013 138 Fresenius Kabi ANDA Approvals, 2010 2013 139 Hikma ANDA Approvals for Injectables, 2010 2013 141 Hospira ANDA Approvals, 2010 2013 143 Mylan Institutional ANDA Approvals, 2010 2013 146 Sagent Strides ANDA Approvals, 2010 2013 149 Sagent Agila ANDA Approvals, 2011 2012 150 Sagent ANDA Approvals, 2010 2013 150 Sandoz ANDA Approvals for Injectables, 2010 2013 152 Sagent Strides ANDA Approvals, 2010 2013 155 Onco Therapies ANDA Approvals, 2011 2013 156 Sun Pharma ANDA Approvals for Injectables, 2010 2013158 Teva ANDA Approvals for Injectables, 2010 2013 160 PharmaChemie ANDA Approvals for Injectables, 2010 2012 160

Injectable Generic and Biosimilar Drugs – Potential Opportunities for Developers 2013


Wockhardt ANDA Approvals for Injectables, 2011 163 FDA ANDA Approvals, January 2011 October 2013 164

List of Figures Faslodex Sales, 2008 2018 (US$ Million) 10 Zoladex Sales, 2008 201813 Eloxatin Sales, 2008 2018 (US$ Million) Taxotere Sales, 2008 2018 (US$ Million) 20 Abraxane Sales, 2008 2018 (US$ Million) 24 Alimta Sales 2008 2018 (US$ Million) 27 Velcade Sales, 2008 2017 (US$ Million) 30 Rituxan/MabThera Sales, 2008 2018 (US$ Million) 33 Herceptin Sales, 2008 2018 (US$ Million) 37 Avastin Sales, 2008 2018 (US$ Million) 40 Erbitux Sales, 2008 2018 (US$ Million) 43 Neupogen Sales, 2008 2018 (US$ Million) 44 Neulasta Sales, 2008 2018 (US$ Million) 50 Humulin Sales, 2008 2018 (US$ Million) 54 Humalog Sales, 2008 2018 (US$ Million) 56 Lantus Sales, 2008 2018 (US$ Million) 58 Apidra Sales, 2008 2018 (US$ Million) 60 Levemir Sales, 2008 2018 (US$ Million) 62 NovoMix & NovoRapid Sales, 2008 2018 (US$ Million) 65 Epogen/Eprex/Procrit Sales, 2008 2018 (US$ Million) 69 Aranesp Sales, 2008 2018 (US$ Million) 74 Lovenox/Clexane Sales, 2008 2018 (US$ Million) 76 Copaxone Sales, 2008 2018 82 Avonex Sales, 2008 2018 (US$ Million) 86 Rebif Sales, 2008 2018 (US$ Million) 88 Betaferon/Betaseron Sales, 2008 2018 (US$ Million) 90 Enbrel Sales, 2008 2012 (US$ Million) 95 Humira Sales, 2008 2018 (US$ Million) 98 Remicade Sales, 2008 2018 (US$ Million) 102 Cubicin Sales, 2008 2018 (US$ Million) 106 Invanz Sales, 2008 2018 (US$ Million) 109 Tygacil Sales, 2008 2018 (US$ Million) 113 Synagis Sales, 2008 2018 (US$ Million) 115 PegIntron Sales, 2008 2018 (US$ Million) 117 Pegasys Sales, 2008 2018 (US$ Million) 119 FDA ANDA Approvals by Company, January 2010 October 2013 124

17

Injectable Generic and Biosimilar Drugs – Potential Opportunities for Developers 2013


FDAANDA Approvals by Company, January 2008 October 2013 125 Injectable Generics Market by Company, 2012 (Volume %) 126

Inquire for Discount @ http://www.reportsnreports.com/contacts/discount.aspx? name=271919. Explore More Report on Pharmaceuticals Market. Contact sales@reportsandreports.com / Call +1 888 391 5441 for further information on “Injectable Generic and Biosimilar Drugs – Potential Opportunities for Developers 2013” report OR for any other market research and intelligence needs you may have for your business.

Injectable Generic and Biosimilar Drugs – Potential Opportunities for Developers 2013

2018 Injectable Generic and Biosimilar Drugs Market : Potential Opportunities for Developers  

Complete Report is Available @ http://www.reportsnreports.com/reports/271919-injectable-generic-and-biosimilar-drugs-potential-opportunities...

Read more
Read more
Similar to
Popular now
Just for you